E-Learning Center
Join Our Network
OncoFacts

Follow Imedex on Twitter

Register for an upcoming conference!

Phone: +1 (678) 242 0906
registration@imedex.com

Fourth Asian Pacific Conference: Perspectives in Lung Cancer


Fourth Asian Pacific Conference:
Perspectives in Lung Cancer

3-4 September 2010

Hong Kong, China

 

Who Should Attend

This educational activity is intended for medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, and other physicians in active clinical practice interested and/or involved in the management of patients with lung cancer.

 

Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the use of at least two biomarkers to predict the efficacy of EGFR-inhibitors, antiangiogenic therapies, and antineoplastic agents in the treatment of patients with lung cancer
  • Describe the epidemiology of lung cancer in Asia and evaluate emerging screening techniques
  • Compare and contrast invasive versus non-invasive (MRI, CT, PET) procedures in the staging of lung cancer
  • Discuss surgical issues and controversies related to the management and treatment of thoracic malignancies
  • Examine the role of radiotherapy and emerging radiotherapeutic techniques in lung cancer
  • Translate the results of at least three recent clinical trials in lung cancer and incorporate them into clinical practice
  • Describe the role of at least three targeted therapies, specifically epidermal growth factor receptor (EGFR)
    and vascular endothelial growth factor (VEGF) inhibitors, in the treatment of thoracic malignancies
  • Analyze current lung cancer research techniques and methodology utilized throughout Asia

Michael Boyer, MB, BS, PhD
Sydney Cancer Center
Sydney, Australia

Gouri Shankar
Bhattacharyya, MD, MPCP, DNB, PhD
AMRI Hospitals
Kolkata, West Bengal, India

Allen KC Chan, MD, PhD
Chinese University of Hong Kong
Hong Kong, China

Anthony Chan, MD
Chinese University of Hong Kong
Hong Kong, China

George G. Chen, MD, PhD
Chinese University of Hong Kong
Hong Kong, China

Ming Chen, MD
Cancer Center of Sun Yat University
Guangzhou, China

Wilfried Eberhardt, MD
West German Cancer Center
Essen, Germany

Min Fan, MD
Fudan University
Shanghai, China

Maya Gottfried, MD
Meir Medical Center
Kfar-Saba, Israel

David Harpole, Jr, MD
Duke University
Durham, North Carolina, United States

Daniel SY Ho, PhD, MPH
The University of Hong Kong
Hong Kong, China

KC Lam, MD
Prince of Wales Hospital
Hong Kong, China

Victor Hofun Lee, MBBD
The University of Hong Kong
Hong Kong, China

Linda Leung, MBBS, MRCP, FHKCP, FHKAM
Prince of Wales Hospital
Hong Kong, China

Zhang Li, MD
Cancer Center of Sun Yat Sin University
Guangzhou, China

Gilberto Lopes, MD
Johns Hopkins Singapore International
Medical Center
Singapore, Republic of Singapore

Brigette Ma, MD, FRCP, MBBS, FRACP
Chinese University of Hong Kong
Hong Kong, China

Tetsuya Mitsudomi, MD
Aichi Cancer Center Hospital
Nagoya, Japan

Tony Mok, MD
Chinese University of Hong Kong
Hong Kong, China

Hiroshi Onishi, MD
University of Yamanashi
Nakakoma, Japan

Keunchil Park, MD
Samsung Medical Center
Seoul, South Korea

Nick Pavlakis, MD
Royal Northshore Hospital
St. Leonards, Australia

Giorgio V. Scagliotti, MD, PhD
University of Torino
Orbassano, Italy

Giovannit Selvaggi, MD
GlaxoSmith-Kline
Orbassano, Italy

Frances A. Shepherd, MD,
FRCPC
Princess Margaret Hospital
University of Toronto
Toronto, Ontario, Canada

Lu Shun, MD, PhD
Shanghai Chest Hospital
Shanghai, China

Sumitra Thongprasert, MD
Chiangmai University
Chiangmai, Thailand

KF To, MD
Chinese University of Hong Kong
Hong Kong, China

WK Tsang, MD, FRCR
Prince of Wales Hospital
Hong Kong, China

Masahiro Tsuboi, MD
Kanagawa Cancer Center
Tokyo, Japan

Mark Vincent, MB, ChB
London Regional Cancer Center
London, Ontario, Canada

Yuk Pui Innes Wan, MBChB, FCSHK, FRCSEd, FHKAM
Chinese University of Hong Kong
Hong Kong, China

Jie Wang, MD, PhD
Beijing Cancer Hospital and Institute
Beijing, China

Matthew Wong, MD
Queen Mary Hospital
Hong Kong, China

Yi-Long Wu, MD
Guangdong General Hospital
Guangzhou, China

James Chih-Hsin Yang, MD, PhD
National Taiwan University
Taipei, Taiwan

Friday, 3 September 2010

8:15                   
Opening remarks

Session I         
State-of-the-art in surgery

8:30                 
The art of radical surgery
David Harpole, Jr, MD

8:55                 
The art of minimal invasive surgery
Masahiro Tsuboi, MD

9:20                 
EBUS versus mediastinoscopy
Yuk Pui Innes Wan, MBChB, FCSHK, FRCS Ed, FHKAM

Session II        
Tobacco and carcinogenesis

9:45                 
Tobacco control in Asia
Daniel SY Ho, PhD, MPH 

10:20               
Carcinogenesis of lung cancer: Smoker vs non-smoker
George G. Chen, MB, PhD

10:45
Coffee break

Session III       
State-of-the-art radiotherapy

11:15               
Novel radiotherapy technology
Min Fan, MD

11:40               
Sterotactic radiotherapy for resectable lung cancer
Hiroshi Onishi, MD 

12:05
Sterotactic and respiratory gated radiotherapy: Local experience
WK Tsang, MD, FRCR

12:30               
Lunch break

Keynote lecture

13:30               
Clinical trial on molecular targeting agent: What is right and what is wrong?  
Made possible by Astra-Zeneca
Frances A. Shepherd, MD, FRCPC

Case presentation I

14:10               
Case presentation
Victor Ho Fun Lee, MBBD

14:25               
Case presentation
Min Fan, MD

Session IV      
Gene signature and biomarkers

14:40               
Gene signature for chemotherapy
Giorgio V Scagliotti, MD, PhD

15:15               
Metagene or magic gene
David Harpole, Jr, MD

15:30               
Coffee break

Session V       
Stage III disease

16:15               
Optimal radiotherapy for stage III NSCLC
Ming Chen, MD

16:40               
Optimal combined modality for stage III NSCLC
Wilfried Eberhardt, MD 

17:05               
Adjourn

Saturday 4 September 2010

Session VI      
State-of-the-art in chemotherapy

8:30                 
Novel development in cytotoxic chemotherapy
Mark Vincent, MD, ChB

8:55                 
Combination of chemotherapy with molecular target therapy:
A good idea that is not so good
Tony Mok, MD

9:20                 
Patient selection for maintenance therapy
Keunchil Park, MD

Session VII     
Novel targets

9:35                 
MAGE A3
Giovannit Selvaggi, MD

9:50                 
ELM-4 ALK: Clinical data
Tetsuya Mitsudomi, MD

10:05               
ELM-4 ALK: Defining a biomarker
Yi-Long Wu, MD

10:20               
IGF-R
KC Lam, MD

10:45               
Irreversible EGFR TKI
James Chih-HsinYang, MD, PhD

11:00               
Vascular disrupting agent and VEGF TKIs
Nick Pavlakis, MD

11:15               
Coffee break

Session VIII    
State-of-the-art diagnosis

11:45               
Radial EBUS and pleuroscopy for diagnosis of lung cancer
Matthew Wong, MD 

12:05               
PET-Scan, MRI, or CT scan: Which is a better tool for early/late stage NSCLC?
Michael Boyer, MB, BS, PhD

12:25               
The challenge of histologic diagnosis in lung cancer: Is adenocarcinoma really an
adenocarcinoma?
KF To, MD

Case presentation II

12:50               
Case presentation
Maya Gottfried, MD

13:05               
Case presentation
Linda Leung, MBBS, MRCP, FHKCP, FHKAM

13:15               
Lunch break

Session IX      
The unfinished EGFR story

14:15               
Cost-effectiveness of EGFR TKI
Gilberto Lopes, MD

14:30               
Detecting EGFR mutation in plasma: DHPLC
Jie Wang, MD, PhD

14:45               
Detecting EGFR mutation in plasma: Digital PCR
Allen KC Chan, MD, PhD

15:00               
EGFR TKI resistance
Lu Shun, MD, PhD

15:15               
Pharmacokinetics of EGFR TKI and treatment out come
Zhang Li, MD  

15:30               
Coffee break

Session X       
Research and development

15:50               
The art and science of phase I study
Brigette Ma, MD, FRCP

16:10               
Getting published in a high impact journal
Anthony KC Chan, MD

16:20               
Current status of lung cancer research in Asia
Sumitra Thongprasert, MD

Current status of lung cancer research in China
Yi-Long Wu, MD

Current status of lung cancer research in India
Gouri Shankar Bhattacharyya, MD, MRCP, DNB, PhD

17:00               
Adjourn

Information coming soon.

Registration Fees

Regular $299
If payment received by 26 August 2010

Full/Onsite $349
If payment received after 26 August 2010

Group discount (physicians only)*-$50
*cannot be combined with any other discounts

Nurses/Residents/Students*$99
*proof of eligibility must accompany registration
*cannot be combined with any other discounts

To Register:

You may register online by 26 August 2010 at www.imedex.com, by calling Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the meeting. To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Group Discounts:

Each one of multiple registrants from the same institute or practice will receive a $50 discount off the published registration fees, provided all registration forms and payments are received together. Only one discount will apply per physician.
Discounts are not available for nurses, residents, or students.

Payment:

To pre-register, registration and payment must be received no later than 26 August 2010. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.

Registration Fee Inclusions:

Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the agenda.

Cancellation:

For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later
than 26 August 2010. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after
26 August 2010.

Imedex does not accept responsibility for covering travel, accommodation, or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

Hyatt Regency Hong Kong, Sha Tin
18 Chak Cheung Street
Sha Tin, New Territories
Hong Kong, China
Tel.: +852 3723 1234
Fax: +852 3723 1235
www.hongkong.shatin.hyatt.com

The Hyatt Regency Hong Kong, Sha Tin, is the first international hotel in the New Territories. The hotel is situated adjacent to the Chinese University of Hong Kong (CUHK), in the Sha Tin district. Conveniently located at University Station, the hotel offers direct access to Tsim Sha Tsui, Hong Kong Island, Lo Wu, and Lok Ma Chau via the Mass Transit Railway (MTR).

The Hyatt Regency Hong Kong, Sha Tin, is only 2 km from Hong Kong Science Park and 30 minutes by taxi from the Hong Kong International Airport. The cost to get from the Hong Kong International Airport to the hotel via taxi is approximately HK$300 (US $40) including tolls, and excluding fee for
luggage and traffic.

For the convenience of attendees, a limited number of rooms have been reserved until 2 August 2010 at a discounted rate of HK$1000 single/double occupancy, plus service charge, currently at 10%. The rate includes one breakfast buffet and an additional breakfast buffet is HK$188 + 10% service charge per person. This rate is not guaranteed outside the conference dates or after 2 August 2010.

To reserve your room please contact the Hyatt Regency Hong Kong, Sha Tin reservations department at +852 3723 1234 or visit the hotel’s website at www.hongkong.shatin.hyatt.com. To receive the group rate, callers must identify themselves as being with the Fourth Annual Meeting: Asia Pacific Perspectives in Lung Cancer group. Internet users must enter the meeting promotional code: G-LC30. Reservation requests received after 2 August 2010 may not be guaranteed the group rate.

Check in is after 14:00 and check out is at12:00.

Letter from the Chairs

Dear Colleague,
It is our pleasure to invite you to the Fourth Asian Pacific onference: Perspectives in Lung Cancer. Held 3-4 September 2010 in Hong Kong, China, attendees from all lung cancer-related disciplines will find it o be a stimulating interactive and educational experience!Created to provide state-of-the-art diagnosis and treatment information, this comprehensive conference focuses on the multimodal management of lung cancer. Guided by expert faculty from Asia, Europe, and North America, this program features interactive case presentations that focus on innovations in diagnosis and staging, and the latest therapies and techniques in the multidisciplinary management of lung cancer. As lung cancer research and treatment are constantly evolving, there are many issues in disease biology, management, and research that are intensely debated among those involved in these filds. Attendees will not only update their knowledge, but confim their current practices, focus on the trends and evolutions worth watching, and receive valuable take-home information on exciting new treatments and approaches. We look forward to welcoming you in Hong Kong, one of the most cosmopolitan, contrasting, and compelling cities in Asia. We know you will find theFourth Asian Pacific onference: Perspectives in Lung Cancer to be a world-class educational event.

Sincerely,
Tony Mok, MD, Chair
Giorgio V. Scagliotti, MD, PhD, Chair
KC Lam, MD, Local Chair
Yi-Long Wu, MD, Local Chair

Organizer

Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

PDF Announcement


Exhibit Manual



This Conference is endorsed by:

CSCO

Hong Kong Cancer Therapy Society

The Hong Kong Cancer
Chemotherapy Society

 

The following companies are supporters of this conference:

Silver:

AstraZeneca

Corporate:

Lilly

Pfizer Oncology

 

Several options are available to companies interested in supporting this conference.
For more information, please contact Imedex at +1 (770) 751 7332, or by email at cme@imedex.com.

Information coming soon.

Opportunities are available to companies interested in exhibiting at this conference.
For more information, please contact Cori Gunter at +1 (678) 242 0712, or by email at c.gunter@imedex.com.